Vaxil Announces Progress on Research and Development Activities

Provided By Globe Newswire

Last update: Oct 12, 2021

Not for distribution by US newswire or in United States

NESS-ZIONA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company provides an update on research on the utilization of P-Esbp polymer as a novel anti-cancer drug.